

Redx to present Preclinical Data on Novel Bacterial Topoisomerase Inhibitors at ASM Microbe 2016 Conference

25 Oct 2016

Redx Pharma is pleased to announce that it will present data on its novel bacterial topoisomerase inhibitors (NBTIs) at the inaugural annual American Society for Microbiology (ASM) Microbe 2016 conference taking place from 16-20 June in Boston, Massachusetts.

Both the rise of antimicrobial resistance and the current antibiotic innovation gap have highlighted the need for novel antimicrobial agents, particularly for the treatment of Gram-negative bacterial infections. Redx is making promising progress in meeting this need following its discovery of a series of NBTIs that demonstrate broad-spectrum antibacterial activity against ESKAPE pathogens and low potential for resistance development.

Redx will be presenting the *in vitro* biological properties of its NBTIs, including activity against multi-drug resistant strains, preliminary assessment of safety profile and data on the *in vivo* exposure level of representative compounds.

No price-sensitive information will be provided during the presentation. A poster containing the relevant information will be made available on the Redx website following the presentation.

Details of the presentation:

- **Title:** *In Vitro* Biology and Pharmacokinetics Evaluation of Novel Bacterial Topoisomerase Inhibitors
- **Session:** 306: Fluoroquinolones and Other Topoisomerase (Therapeutics and Prevention Track)
- **Date:** 19 June 2016
- **Time:** 12:30-14:30 EST
- **Poster Location:** BCEC, Exhibit and Poster Hall, Halls A and B
- **Poster Number:** SU-463

[Download the presentation poster SU-463, ASM Microbe 2016](#)